

Indivior Publications 2020

Manuscript

Treatment of Opioid Use Disorder

1. Ling W, Nadipelli VR, Aldridge A, Ronquest N, Solem C, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, Heidbreder C (2020) Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study. *J Addict Med.* September/October 2020-Volume 14- Issue 5- p e233-e240.
<https://doi.org/10.1097/ADM.0000000000000647>
2. Andorn A, Haight B, Shinde S, Fudala P, Zhao S, Heidbreder C, Learned S, Fox NL, Nadipelli VR, Hassman D, Rutrick D (2020) Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. *J Clin Psychopharmacol.* May/Jun 2020;40(3):231-239.
<https://doi.org/10.1097/JCP.0000000000001195>
3. Reimer J, Vogelmann T, Trümper D, Scherbaum N (2020) Impact of Buprenorphine Dosage on the Occurrence of Relapses in Patients with Opioid Dependence. *Eur Addict Res.* 2020;26(2):77-84. doi: 10.1159/000505294. Epub 2020 Jan 15. <https://doi.org/10.1159/000505294>
4. Algera MA, Olofsen E, Moss L, Dobbins RL, Niesters M, van Velzen M, Groeneveld GJ, Heuberger J, Laffont CM, Dahan A (2020) Tolerance to opioid-induced respiratory depression in chronic high-dose opioid consumers: a model-based comparison with opioid-naïve individuals. *Clinical Pharmacology & Therapeutics.* 2021 Mar;109(3):637-645. doi: 10.1002/cpt.2027. Epub 2020 Oct 5.
<https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2027>
5. Kranzler HR, Lynch K, Crist R, Hartwel E, Le Moigne A, Laffont CM, Andorn AC (2020) Moderation by a Delta-Opioid Receptor Gene Polymorphism of the Therapeutic Effect of Extended-Release Buprenorphine in Opioid Use Disorder. *Int J Neuropsychopharm.* 2021 Feb 15;24(2):89-96. doi: 10.1093/ijnp/pyaa069.
<https://academic.oup.com/ijnp/article/24/2/89/5905003>
6. Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM (2020) Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase 2 and Phase 3 Trials. *Clin Pharmacokinet.* 2021 Apr;60(4):527-540. doi: 10.1007/s40262-020-00957-0. Epub 2020 Nov 2. <https://link.springer.com/article/10.1007/s40262-020-00957-0>

Treatment of Schizophrenia

1. LeMoigne A, Fava M, Csernansky J, Newcomer C, Graham J (2020). Reanalysis of a phase 3 trial of a monthly extended-release risperidone injection for the treatment of acute schizophrenia. *Journal of Clinical Psychopharmacology*. 2021 Jan/Feb 01;41(1):76-77. doi: 10.1097/JCP.0000000000001319.
https://journals.lww.com/psychopharmacology/Fulltext/2021/01000/Reanalysis_of_a_Phase_3_Trial_of_a_Monthly.17.aspx